Latest disclosed round
Series B
- Date
- 2024-05-01
- Amount
- GBP 35m
- Sector
- Biotech & techbio
- Companies House
- 08183505
Series B
LabGenius
AI antibody discovery
CandidateSeries BLondon
Evidence status
Review retained
- Identity
- Candidate
- Match
- High candidate
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
9 linked investors
Funding record
3 disclosed rounds
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2024-05-01 | Series B | £35M | M Ventures (Merck CVC), Octopus Ventures, LG Corp, Atomico, Kindred Capital, Lux Capital, Obvious Ventures |
| 2020-10-29 | Series A extension | $15M additional (Series A total $25M) | Atomico, Lux Capital, Obvious Ventures, Kindred Capital, Inovia Capital |
| 2019-10-22 | Series A | $10M+ (also €11.5M) | Lux Capital, Obvious Ventures, Felicis Ventures, Inovia Capital, Gigafund, Air Street Capital, Kindred Capital, Chris Gibson (angel) |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.